This doesn't look good to me. Are they going into higher gear re vaccines?

[Guest guest]

Congress Program

 

Sunday December 7, 2008

 

Plenary session 1: Setting the Scene11.00

 

Welcome

Ray Spier, University of Surrey, UK

11.10 Future of vaccine

discovery

Adel Mahmoud, Princeton University, USA

11.45

Duration of immunity following vaccination: How long it can last

and how we can make it better

Mark Slifka, Oregon Health & Science University, USA

12.10

Development of self-administrative vaccine by MucoRiceTM

System

Hiroshi Kiyono, University of Tokyo, Japan

12.35

Pathogenic epitopes, heterologous immunity, and vaccine design

Raymond Welsh, University of Massachusetts Medical School, USA

 

13.00

Lunch and Exhibition Hall

viewing

 

Plenary session 2: Major Infectious Disease Targets14.00

 

TB vaccine

development

 

Jerald C. Sadoff, Aeras Global TB Vaccine Foundation, USA

14.25

Developing HIV vaccines with protective antibody

responses

Shan Lu, University of Massachusetts Medical School, SA

14.50

New vectored vaccines for

malaria

Adrian Hill, The Jenner Institute Oxford, UK

15.15

Oral Abstract Presentations (10 minutes each)

15.35

Poster Session, Exhibits and Coffee

Plenary session 3: Non-traditional Vaccines16.00

 

Of mice and men (and dogs): Clinical development of Xenogeneic DNA

vaccines for

cancer

Jedd D. Wolchok, Memorial Sloan-Kettering Cancer Center, USA

16.25

Computer-driven vaccine design: from concept to reality

Annie DeGroot, EpiVax Inc., USA

16.50 – 17.30

Oral Abstract Presentations (10 minutes each)

 

Monday December 8, 2008

 

Plenary session 4: Adjuvants08.30 Innate immune

pattern recognition receptors and vaccine adjuvants

Kate A. Fitzgerald, University of Massachusetts Medical School, USA

08.55 Use of CpG oligonucleotides as a vaccine adjuvant

Dennis Klinman, NCI-Frederick, USA

09.30 Oral Abstract Presentations [10 minutes each]

10.20 Poster Session, Exhibits and Coffee

Plenary session 5: Delivery systems11.00 Novel adenovirus

vector-based vaccines for HIV-1

Dan Barouch, Harvard Medical School, USA

11.25 Vaccination into or onto the skin: Advantages, accomplishments,

actualizations, and adumbrations of the cutaneous route

Bruce G. Weniger, Centers for Disease Control and Prevention, USA

11.50 Oral Abstract Presentations [10 minutes each]

12.30 Poster Session, Exhibit hall and Lunch

Plenary Session 6 14.15 Influenza immunization of health

care workers: A patient safety imperative

Gregory A. Poland, Mayo Vaccine Research Group, USA

15.15 Young Vaccinologists Session [Presentations to be selected from

submitted abstracts]

15.45 Poster Session, Exhibits and Coffee

16.30 – 18.00

 

Breakout Sessions

 

Breakout session 1: Late Breakers Abstracts

 

Breakout session 2: Scale-up Production and Stability16.30

Stability of vaccines

Rich Costantino, USA

16.55 – 18.00 Oral Abstract Presentations [10 minutes each]

19.30 Coaches depart hotel for the congress dinner at the Museum of

Science

 

Tuesday December 9, 2008

 

Plenary session 7: Novel Bacterial Vaccines08.30

Vaccines: an health insurance of the 21st century

Rino Rappuoli, Novartis Vaccines and Diagnostics, Italy

08.55 Development of a novel Staphylococcus aureus vaccine based on a

conserved protein antigen

John W. Shiver, Merck and Co Inc., USA

09.20 Pneumococcal conjugate vaccines: what do we know and what do we

need?

Jennifer Schranz, Wyeth Pharmaceuticals, USA

09.45 Oral Abstract Presentations [10 minutes each]

10.30 Poster Session, Exhibits and Coffee

Plenary session 8: Emerging Infectious Disease & Biodefense

11.00 Emerging viruses vaccines

Alan Barrett, University of Texas Medical Branch, USA

11.25 Influenza

John Oxford, Retroscreen Virology Ltd, UK

11.50 Oral Abstract Presentations [10 minutes each]

12.30 Poster Session, Exhibits and Lunch

Plenary sessions 9: Vaccine Policy and public health

issues14.00 Improving on Mother Nature's immunogenicity

Peter Nara, Biological Mimetics Inc, USA

14.25 Current & future U.S. Government funding for vaccine R & D

and acquisition

Dack Dalrymple, Dalrymple & Associates, LLC, USA

14.50 Implementing vaccination programs in developing countries

Jon Andrus, Pan American Health Organization, USA

15.15 Communicating to the public about vaccines

Ray Spier, University of Surrey, UK

15.40 Closing Summary and end of conference

 

http://www.vaccinecongress.com/program.htm

 

 

avast! Antivirus: Outbound message clean.

Virus Database (VPS): 081016-0, 16/10/2008Tested on: 17/10/2008 11:59:15 PMavast! - copyright © 1988-2008 ALWIL Software.